STML News and Press, Stemline Therapeutics Inc. From 03/16/20

Stemline Therapeutics, Inc. (STML) Q4 2019 Results Earnings Conference Call March 16, 2020, 08:00 AM ET Company Participants Kenneth Hoberman - COO Ivan Bergstein - Founder, President, CEO & Chairman David Gionco - Senior VP of Finance & CAO Robert Francomano - Chief Co...

Stemline Therapeutics (NASDAQ: STML ): Q4 GAAP EPS of -$0.38 misses by $0.03 . More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Net revenue for ELZONRIS® was $11.8 million for the fourth quarter Conference call and live webcast scheduled for Monday, March 16 th , at 8:00 AM ET NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical c...

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the company will host a conference call and webcast on ...

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that management will present at the Cowen 40 th Annual Healt...

Nearly all men can stand adversity, but if you want to test a man's character, give him power. " - Abraham Lincoln It has been a tough start to 2020 for Stemline Therapeutics ( STML ), or at least its stock. The shares dropped some 35% on January 13th when the company provided preli...

The following slide deck was published by Stemline Therapeutics, Inc. in conjunction with this Read more ...

Gainers: RTI Surgical RTIX  +66% . More news on: IRIDEX Corporation, Inpixon, Gritstone Oncology, Inc., Stocks on the move, , Read more ...

Shares of Stemline Therapeutics (NASDAQ: STML) were down 34% at 11:42 a.m. EST after the company released disappointing preliminary fourth-quarter results. The biotech estimates that it sold $11.8 million worth of Elzonris, a drug that treats blastic plasmacytoid dendritic cell neoplasm (...

Stemline Therapeutics (NASDAQ: STML )  -22%  on preliminary Q4 revenue. More news on: Stemline Therapeutics, Inc., Avinger, Inc., DURECT Corporation, Stocks on the move, Read more ...